

List of References for Indolent Lymphoma

- Ansell, S.M. (2013) Malignant B cells at the helm in follicular lymphoma. *J Clin Oncol*, 31, 2641-2642.
- Arcaini, L. & Bruno, R. (2010) Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. *Curr Clin Pharmacol*, 5, 74-81.
- Ardeshtna, K., Qian, H., Smith, P. & al., E. (2010) An intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2, and 3a). A preliminary analysis. *Blood*, 116, 6.
- Bierman, P.J., Vose, J.M., Anderson, J.R., Bishop, M.R., Kessinger, A. & Armitage, J.O. (1997) High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. *J Clin Oncol*, 15, 445-450.
- Carson, K.R. & Bennett, C.L. (2009) Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. *Leuk Lymphoma*, 50, 323-324.
- Casulo, C., Byrtek, M., Dawson, K. L., Zhou, X., Farber, C. M., Flowers, C. R., ... & Friedberg, J. W. (2015). Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study. *Journal of Clinical Oncology*, 33(23), 2516-2522.**
- Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippenstein, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. *J Clin Oncol*, 17, 1244.
- Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. *J Clin Oncol*, 25, 579-586.
- Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V., Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Stamatoullas, A., Milpied, N., Boue, F., Taillan, B., Lederlin, P., Najman, A., Thieblemont, C., Montestruc, F., Mathieu-Boue, A., Benzohra, A. & Solal-Celigny, P. (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. *Blood*, 97, 101-106.
- Czuczman, M. (2006) Controversies in Follicular Lymphoma: "Who, What, When, Where, and Why?" (Not necessarily in that order!). *ASH Education Book*.
- Czuczman, M.S., Grillo-Lopez, A.J., White, C.A., Saleh, M., Gordon, L., LoBuglio, A.F., Jonas, C., Klippenstein, D., Dallaire, B. & Varns, C. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. *J Clin Oncol*, 17, 268-276.
- Czuczman, M.S., Koryzna, A., Mohr, A., Stewart, C., Donohue, K., Blumenson, L., Bernstein, Z.P., McCarthy, P., Alam, A., Hernandez-Ilizaliturri, F., Skipper, M., Brown, K., Chanan-Khan, A., Klippenstein, D., Loud, P., Rock, M.K., Benyunes, M., Grillo-Lopez, A. & Bernstein, S.H. (2005) Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. *J Clin Oncol*, 23, 694-704.

- Czuczman, M.S., Weaver, R., Alkuzweny, B., Berlfein, J. & Grillo-Lopez, A.J. (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. *J Clin Oncol*, 22, 4711-4716.
- Dupuis, J., Berriolo-Riedinger, A., Julian, A., Brice, P., Tychyj-Pinel, C., Tilly, H., Mounier, N., Gallamini, A., Feugier, P., Soubeyran, P., Colombat, P., Laurent, G., Berenger, N., Casasnovas, R.O., Vera, P., Paone, G., Xerri, L., Salles, G., Haioun, C. & Meignan, M. (2012) Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. *J Clin Oncol*, 30, 4317-4322.
- Federico, M., Luminari, S., Dondi, A., Tucci, A., Vitolo, U., Rigacci, L., Di Raimondo, F., Carella, A.M., Pulsoni, A., Merli, F., Arcaini, L., Angrilli, F., Stelitano, C., Gaidano, G., Dell'olio, M., Marcheselli, L., Franco, V., Galimberti, S., Sacchi, S. & Brugiattelli, M. (2013) R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. *J Clin Oncol*, 31, 1506-1513.
- Ferreri, A.J., Ponzoni, M., Guidoboni, M., De Conciliis, C., Resti, A.G., Mazzi, B., Lettini, A.A., Demeter, J., Dell'Oro, S., Doglioni, C., Villa, E., Boiocchi, M. & Dolcetti, R. (2005) Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. *J Clin Oncol*, 23, 5067-5073.
- Fisher, R.I., LeBlanc, M., Press, O.W., Maloney, D.G., Unger, J.M. & Miller, T.P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. *J Clin Oncol*, 23, 8447-8452.
- Fisher, R. I., & Khan, N. (2015). Is Observation Dead in Follicular Lymphoma? No, But the Apoptosis Pathway Has Been Activated. *Journal of the National Comprehensive Cancer Network*, 13(3), 363-366.**
- Franco, V., Florena, A.M. & Iannitto, E. (2003) Splenic marginal zone lymphoma. *Blood*, 101, 2464-2472.
- Furman, R.R., Sharman, J.P., Coutre, S.E., Cheson, B.D., Pagel, J.M., Hillmen, P., Barrientos, J.C., Zelenetz, A.D., Kipps, T.J., Flinn, I., Ghia, P., Eradat, H., Ervin, T., Lamanna, N., Coiffier, B., Pettitt, A.R., Ma, S., Stilgenbauer, S., Cramer, P., Aiello, M., Johnson, D.M., Miller, L.L., Li, D., Jahn, T.M., Dansey, R.D., Hallek, M. & O'Brien, S.M. (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med*, 370, 997-1007.**
- Ganti, A.K., Weisenburger, D.D., Smith, L.M., Hans, C.P., Bociek, R.G., Bierman, P.J., Vose, J.M. & Armitage, J.O. (2006) Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. *Ann Oncol*, 17, 920-927.
- Ghielmini, M., Schmitz, S.F., Cogliatti, S.B., Pichert, G., Hummerjohann, J., Waltzer, U., Fey, M.F., Betticher, D.C., Martinelli, G., Peccatori, F., Hess, U., Zucca, E., Stupp, R., Kovacsics, T., Helg, C., Lohri, A., Bargetzi, M., Vorobiof, D. & Cerny, T. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. *Blood*, 103, 4416-4423.
- Gopal, A.K., Kahl, B.S., de Vos, S., Wagner-Johnston, N.D., Schuster, S.J., Jurczak, W.J., Flinn, I.W., Flowers, C.R., Martin, P., Viardot, A., Blum, K.A., Goy, A.H., Davies, A.J., Zinzani, P.L., Dreyling, M., Johnson, D., Miller, L.L., Holes, L., Li, D., Dansey, R.D., Godfrey, W.R.**

& Salles, G.A. (2014) PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. *N Engl J Med*, 370, 1008-1018.

- Gribben, J.G. (2010) Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. *Curr Opin Oncol*, 22, 424-430.
- Gribben, J.G., Neuberger, D., Freedman, A.S., Gimmi, C.D., Pesek, K.W., Barber, M., Saporito, L., Woo, S.D., Coral, F., Spector, N. & et al. (1993) Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. *Blood*, 81, 3449-3457.
- Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. *J Clin Oncol*, 17, 3835-3849.
- Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. *Blood*, 106, 3725-3732.
- Hiddemann, W., & Cheson, B. D. (2014). How we manage follicular lymphoma. *Leukemia*, 28(7), 1388-1395.
- Hiraga, J., Tomita, A., Sugimoto, T., Shimada, K., Ito, M., Nakamura, S., Kiyoi, H., Kinoshita, T. & Naoe, T. (2009) Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. *Blood*, 113, 4885-4893.
- Jacobson, C.A. & Freedman, A.S. (2012) Early stage follicular lymphoma, current management and controversies. *Curr Opin Oncol*, 24, 475-479.
- Kahl, B.S., Bartlett, N.L., Leonard, J.P., Chen, L., Ganjoo, K., Williams, M.E., Czuczman, M.S., Robinson, K.S., Joyce, R., van der Jagt, R.H. & Cheson, B.D. (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. *Cancer*, 116, 106-114.
- Keehn, C.A., Belongie, I.P., Shistik, G., Fenske, N.A. & Glass, L.F. (2007) The diagnosis, staging, and treatment options for mycosis fungoides. *Cancer Control*, 14, 102-111.
- Khoury, I.F., McLaughlin, P., Saliba, R.M., Hosing, C., Korbl, M., Lee, M.S., Medeiros, L.J., Fayad, L., Samaniego, F., Alousi, A., Anderlini, P., Couriel, D., de Lima, M., Giral, S., Neelapu, S.S., Ueno, N.T., Samuels, B.I., Hagemeister, F., Kwak, L.W. & Champlin, R.E. (2008) Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. *Blood*, 111, 5530-5536.
- Kim, E.J., Hess, S., Richardson, S.K., Newton, S., Showe, L.C., Benoit, B.M., Ubriani, R., Vittorio, C.C., Junkins-Hopkins, J.M., Wysocka, M. & Rook, A.H. (2005) Immunopathogenesis and therapy of cutaneous T cell lymphoma. *J Clin Invest*, 115, 798-812.
- Kridel, R., Sehn, L.H. & Gascoyne, R.D. (2012) Pathogenesis of follicular lymphoma. *J Clin Invest*, 122, 3424-3431.

- Lecuit, M., Abachin, E., Martin, A., Poyart, C., Pochart, P., Suarez, F., Bengoufa, D., Feuillard, J., Lavergne, A., Gordon, J.I., Berche, P., Guillemin, L. & Lortholary, O. (2004) Immunoproliferative small intestinal disease associated with *Campylobacter jejuni*. *N Engl J Med*, 350, 239-248.
- Liu, H., Ye, H., Ruskone-Fourmestraux, A., De Jong, D., Pileri, S., Thiede, C., Lavergne, A., Boot, H., Caletti, G., Wundisch, T., Molina, T., Taal, B.G., Elena, S., Thomas, T., Zinzani, P.L., Neubauer, A., Stolte, M., Hamoudi, R.A., Dogan, A., Isaacson, P.G. & Du, M.Q. (2002) T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to *H. pylori* eradication. *Gastroenterology*, 122, 1286-1294.
- Lopez-Guillermo, A., Cabanillas, F., McLaughlin, P., Smith, T., Hagemeister, F., Rodriguez, M.A., Romaguera, J.E., Younes, A., Sarris, A.H., Preti, H.A., Pugh, W. & Lee, M.S. (1998) The clinical significance of molecular response in indolent follicular lymphomas. *Blood*, 91, 2955-2960.
- Maddocks, K. & Blum, K.A. (2014) Ibrutinib in B-cell Lymphomas. *Curr Treat Options Oncol*, 15, 226-237.**
- Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J.V., Dmoszynska, A., Raposo, J.C., Offner, F.C., Gomez-Codina, J., Belch, A., Cunningham, D., Wassner-Fritsch, E. & Stein, G. (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. *J Clin Oncol*, 26, 4579-4586.
- Mazloom, A., Medeiros, L.J., McLaughlin, P.W., Reed, V., Cabanillas, F.F., Fayad, L.E., Pro, B., Gonzalez, G., Iyengar, P., Urbauer, D.L. & Dabaja, B.S. (2010) Marginal zone lymphomas: factors that affect the final outcome. *Cancer*.
- Morschhauser, F., Radford, J., Van Hoof, A., Botto, B., Rohatiner, A.Z., Salles, G., Soubeyran, P., Tilly, H., Bischof-Delaloye, A., van Putten, W.L., Kysstra, J.W. & Hagenbeek, A. (2013) 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent trial. *J Clin Oncol*, 31, 1977-1983.
- Nastoupil, L.J., Rai, A., Lipscomb, J., Williams, J.N., Wa4rd, K., Howard, D.H. & Flowers, C.R. (2013) Patterns of care and outcomes of anthracyclines in Grade 3 follicular lymphoma (FL). *Blood*, 122.**
- Press, O.W. & Palanca-Wessels, M.C. (2013) Selection of first-line therapy for advanced follicular lymphoma. *J Clin Oncol*, 31, 1496-1498.
- Press, O.W., Unger, J.M., Rimsza, L.M., Friedberg, J.W., LeBlanc, M., Czuczman, M.S., Kaminski, M., Braziel, R.M., Spier, C., Gopal, A.K., Maloney, D.G., Cheson, B.D., Dakhil, S.R., Miller, T.P. & Fisher, R.I. (2013) Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. *J Clin Oncol*, 31, 314-320.
- Psyrris, A., Papageorgiou, S. & Economopoulos, T. (2008) Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. *Ann Oncol*, 19, 1992-1999.
- Pyo, J., Won Kim, K., Jacene, H.A., Sakellis, C.G., Brown, J.R. & Van den Abbeele, A.D. (2013) End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. *Clin Cancer Res*, 19, 6566-6577.**
- Relander, T., Johnson, N.A., Farinha, P., Connors, J.M., Sehn, L.H. & Gascoyne, R.D. (2010) Prognostic factors in follicular lymphoma. *J Clin Oncol*, 28, 2902-2913.

- Roggero, E., Zucca, E., Mainetti, C., Bertoni, F., Valsangiacomo, C., Pedrinis, E., Borisch, B., Piffaretti, J.C., Cavalli, F. & Isaacson, P.G. (2000) Eradication of *Borrelia burgdorferi* infection in primary marginal zone B-cell lymphoma of the skin. *Hum Pathol*, 31, 263-268.
- Rosen, S.T. & Querfeld, C. (2006) Primary cutaneous T-cell lymphomas. *Hematology Am Soc Hematol Educ Program*, 323-330, 513.
- Roulland, S., Morgado, E., Kelly, R., Sungalee, J.S., Colombat, P., Solal-Celigny, P., Salles, G.A., Vineis, P. & Nadel, B. (2013) Circulating t(14;19)+ cells as predictive markers of follicular lymphoma development. *Blood*, 122**
- Rummel, M.J., Niederle, N., Maschmeyer, G., Banat, G.A., von Grunhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., Kaiser, U., Weidmann, E., Durk, H., Ballo, H., Stauch, M., Roller, F., Barth, J., Hoelzer, D., Hinke, A. & Brugger, W. (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet*, 381, 1203-1210.
- Ruskone-Fourmestraux, A., Fischbach, W., Aleman, B.M., Boot, H., Du, M.Q., Megraud, F., Montalban, C., Raderer, M., Savio, A. & Wotherspoon, A. (2011) EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. *Gut*, 60, 747-758.
- Salles, G., Seymour, J.F., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J.V., Brice, P., Caballero, D., Haioun, C., Pedersen, L.M., Delmer, A., Simpson, D., Leppa, S., Soubeyran, P., Hagenbeek, A., Casasnovas, O., Intragumtornchai, T., Ferme, C., da Silva, M.G., Sebban, C., Lister, A., Estell, J.A., Milone, G., Sonet, A., Mendila, M., Coiffier, B. & Tilly, H. (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. *Lancet*, 377, 42-51.
- Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J.O., Arranz-Saez, R., Au, W.Y., Bellei, M., Brice, P., Caballero, D., Coiffier, B., Conde-Garcia, E., Doyen, C., Federico, M., Fisher, R.I., Garcia-Conde, J.F., Guglielmi, C., Hagenbeek, A., Haioun, C., LeBlanc, M., Lister, A.T., Lopez-Guillermo, A., McLaughlin, P., Milpied, N., Morel, P., Mounier, N., Proctor, S.J., Rohatiner, A., Smith, P., Soubeyran, P., Tilly, H., Vitolo, U., Zinzani, P.L., Zucca, E. & Montserrat, E. (2004) Follicular lymphoma international prognostic index. *Blood*, 104, 1258-1265.
- Swenson, W.T., Wooldridge, J.E., Lynch, C.F., Forman-Hoffman, V.L., Chrischilles, E. & Link, B.K. (2005) Improved survival of follicular lymphoma patients in the United States. *J Clin Oncol*, 23, 5019-5026.
- Thieblemont, C., Berger, F., Dumontet, C., Moullet, I., Bouafia, F., Felman, P., Salles, G. & Coiffier, B. (2000) Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. *Blood*, 95, 802-806.
- Trotman, J., Fournier, M., Lamy, T., Seymour, J.F., Sonet, A., Janikova, A., Shpilberg, O., Gyan, E., Tilly, H., Estell, J., Forsyth, C., Decaudin, D., Fabiani, B., Gabarre, J., Salles, B., Van Den Neste, E., Canioni, D., Garin, E., Fulham, M., Vander Borgh, T. & Salles, G. (2011) Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. *J Clin Oncol*, 29, 3194-3200.
- Tychyj-Pinel, C., Ricard, F., Fulham, M., Fournier, M., Meignan, M., Lamy, T., Vera, P., Salles, G. & Trotman, J. (2014) PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. *Eur J Nucl Med Mol Imaging*, 41, 408-415.**

- Van Besien, K. (2009) Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. *Hematology Am Soc Hematol Educ Program*, 610-618.
- van Besien, K., Loberiza, F.R., Jr., Bajorunaite, R., Armitage, J.O., Bashey, A., Burns, L.J., Freytes, C.O., Gibson, J., Horowitz, M.M., Inwards, D.J., Marks, D.I., Martino, R., Maziarz, R.T., Molina, A., Pavlovsky, S., Pecora, A.L., Schouten, H.C., Shea, T.C., Lazarus, H.M., Rizzo, J.D. & Vose, J.M. (2003) Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. *Blood*, 102, 3521-3529.
- van Oers, M.H., Van Glabbeke, M., Giurgea, L., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E., van t Veer, M., Vranovsky, A., Holte, H. & Hagenbeek, A. (2010) Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. *J Clin Oncol*, 28, 2853-2858.
- Wahlin, B.E., Yri, O.E., Kimby, E., Holte, H., Delabie, J., Smeland, E.B., Sundstrom, C., Christensson, B. & Sander, B. (2012) Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. *Br J Haematol*, 156, 225-233.
- Weng, W.K. & Levy, S. (2003) Hepatitis C virus (HCV) and lymphomagenesis. *Leuk Lymphoma*, 44, 1113-1120.
- Westin, J.R., Chu, F., Zhang, M., Fayad, L.E., Kwak, L.W., Fowler, N., Romaguera, J., Hagemester, F., Fanale, M., Samaniego, F., Feng, L., Baladandayuthapani, V., Wang, Z., Ma, W., Gao, Y., Wallace, M., Vence, L.M., Radvanyi, L., Muzzafar, T., Rotem-Yehudar, R., Davis, R.E. & Neelapu, S.S. (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. *Lancet Oncol*, 15, 69-77.**
- Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P.S. & White, C.A. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. *J Clin Oncol*, 20, 3262-3269.
- Yahalom, J. (2014) Radiotherapy of follicular lymphoma: updated role and new rules. *Curr Treat Options Oncol*, 15, 262-268.**
- Yang, Z.Z. & Ansell, S.M. (2012) The tumor microenvironment in follicular lymphoma. *Clin Adv Hematol Oncol*, 10, 810-818.